For a newborn in the NICU with a suspected bloodstream infection, the clock is the enemy. The current diagnostic standard, a blood culture, can take two to five days to return a result. Melio, a Santa Clara-based biotech startup, is building a platform designed to collapse that timeline to under three hours, delivering a pathogen ID and resistance profile directly from a whole blood sample without the need for a culture [Melio, retrieved 2024].
The race against sepsis
Melio’s core bet is a hardware-plus-software system that integrates microfluidics, proprietary assays, and a machine learning engine. The process begins with a small blood sample, which is loaded into a cartridge and analyzed using a technique called digital DNA melting genomic profiling. This method generates a unique genomic signature for any pathogen present, which Melio’s algorithms then match against a reference library to identify the specific bacteria or fungus and flag known antimicrobial resistance markers [Perplexity Sonar Pro Brief, retrieved 2024]. The company claims its test can identify 99% of the most common pathogens [Melio, retrieved 2024].
A grant-driven path to the clinic
Founded in 2018, Melio has navigated the long, capital-intensive road of medical device development through non-dilutive funding and accelerator support. Its most significant validation to date is a $3.5 million seed-stage grant awarded in January 2025 by CARB-X [CARB-X, January 2025]. This funding is earmarked for development work, specifically for the platform’s application in neonatal sepsis. The company has also been through programs with SOSV’s IndieBio and the UC San Diego Institute for the Global Entrepreneur [SOSV, retrieved 2026] [IndieBio, retrieved 2026].
| Metric | Value |
|---|---|
| 2025 Seed Grant | $3.5M |
The competitive and regulatory landscape
Melio is entering a field with established players and high technical hurdles. Competitors like T2 Biosystems have commercialized rapid, culture-free diagnostic systems, but often for a more limited panel of pathogens. Melio’s differentiation rests on its claim of a universal, software-updatable test. This ambition comes with significant challenges:
- Clinical validation. The product is still in development and not yet commercialized [Perplexity Sonar Pro Brief, retrieved 2024].
- Commercial execution. Successfully deploying a new hardware platform in hospital settings involves navigating complex procurement cycles.
- Market education. Convincing hospitals to adopt a new, paradigm-shifting diagnostic will require demonstrating a clear return on investment.
The company’s focus on neonatal sepsis, while addressing a dire need, also represents a strategically narrow initial market. Success there could provide the clinical proof point needed to expand into broader adult sepsis and bloodstream infection diagnostics.